Spots Global Cancer Trial Database for Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
Official Title: An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Study ID: NCT00530816
Conditions
Interventions
Study Description
Brief Summary: To evaluate the best overall response rate, safety and tolerability of carfilzomib in patients with relapsed or refractory multiple myeloma.
Detailed Description: Two groups of patients with multiple myeloma were initially studied: bortezomib-naïve and bortezomib-treated. Following Amendment 2, only bortezomib-naïve patients were enrolled. Study results were reported in 2 parts, depending on whether a patient received prior bortezomib.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
Tower Cancer Research Foundation, Beverly Hills, California, United States
Therapeutic Research Institute of Orange County, Laguna Hills, California, United States
Rocky Mountain Blood and Marrow Transplant Program, Denver, Colorado, United States
Oncology & Hematology Assoc. of W. Broward, Tamarac, Florida, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Northwestern University, Chicago, Illinois, United States
Orchard Research, Skokie, Illinois, United States
University of Kentucky College of Medicine, Lexington, Kentucky, United States
Montgomery Cancer Center, Mount Sterling, Kentucky, United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
Hattiesburg Clinic, Hattiesburg, Mississippi, United States
Jackson Oncology Associates, Jackson, Mississippi, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
St. Vincent's Comprehensive Cancer Center, New York, New York, United States
Summa Health System, Akron, Ohio, United States
Gabrail Cancer Center, Canton, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
Dayton Clinical Oncology Program, Dayton, Ohio, United States
Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States
Harrington Cancer Center, Amarillo, Texas, United States
Texas Oncology Cancer Center, Austin, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
University of Calgary, Calgary, Alberta, Canada
University of Alberta Cross Cancer Institute, Edmonton, Alberta, Canada
University of Toronto Princess Margaret Hospital, Toronto, Ontario, Canada
Royal Victoria Hospital, Montreal, Quebec, Canada
Contact Details
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
